What Laboratorios Salvat does

Laboratorios Salvat is a Spanish family-owned pharmaceutical company founded in 1955, headquartered in Barcelona and operating across ENT (otolaryngology), ophthalmology, gastroenterology, urology, and consumer healthcare. It employs roughly 500 people, generates over €100M in annual revenue (2025), and sells in more than 50 countries with approximately 40% of sales generated internationally. The group owns three production facilities in Spain (Barcelona corporate and manufacturing, Pharmaloop near Madrid, and Alcalá de Henares) plus a U.S. subsidiary in Tamarac, Florida (Salvat USA, established 2006). Reported 2025 EBITDA growth of 25% coincides with a leadership transition to CEO Jordi Muntañola.

The company's competitive position rests on a proprietary technology stack rather than discovery science. Its core platform is Blow-Fill-Seal (BFS) aseptic manufacturing for sterile single-dose liquid formulations, complemented by the IMPACT-SVT nanoemulsion technology, an orally dispersible tablet platform, and the BONECURE cell therapy program developed with Histocell. Flagship brands include Cetraxal and Otovel (otic fluoroquinolones), Clotic (an antifungal for otomycosis holding an FDA Orphan Drug Designation granted in October 2025), Cristalmina (a chlorhexidine antiseptic that scaled from €3M to €9M over seven years), and Monolitum (gastroenterology). R&D intensity is reported at 15% of turnover (€10M+), and three FDA approvals have been secured across the product portfolio, with an additional FDA approval granted in October 2024 for sterile BFS drug manufacturing at the Pharmaloop site.

The business model combines three revenue streams: (1) proprietary prescription and consumer healthcare products distributed through pharmacy channels in core European and Latin American markets, (2) international licensing and distribution partnerships—WraSer/Arbor in the United States and Lee's Pharmaceutical in China (Phase III for Cetraxal)—and (3) third-party CDMO services through the Pharmaloop subsidiary, acquired in 2017 and now operating from a €65M plant with 350M units/year capacity rising to 500M units at full ramp. Pharmaloop's FDA approval (October 2024) opens U.S. contract manufacturing as a fourth strategic lever alongside the proprietary portfolio.

Name

Laboratorios Salvat

Legal name

Laboratorios Salvat, S.A.

Website

https://svt.com

Company type

Private

Founded year

1955

Operating status

Operating

Headcount range

251–500 employees

Short description

Laboratorios Salvat is a Spanish family-owned pharmaceutical company founded in 1955, specializing in ENT, ophthalmology, gastroenterology, and consumer healthcare products. It manufactures sterile single-dose formulations via proprietary Blow-Fill-Seal technology and operates a CDMO business through its Pharmaloop subsidiary.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

• Prescription pharmaceuticals
• Blow-fill-seal manufacturing
• Ophthalmic therapeutics
• Otic medications
• Sterile contract manufacturing

Headquarters

HQ city

Esplugas De Llobregat

HQ country

Spain

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of proprietary pharmaceutical products across therapeutic areas including otolaryngology, ophthalmology, gastroenterology, and consumer healthcare. Products include prescription drugs and OTC consumer health products sold through pharmacies and healthcare providers.
2. International Licensing and Royalties: International sales represent approximately 40% of business. Licensing agreements with regional distributors including Lee's Pharmaceutical (China), WraSer/Arbor Pharmaceuticals (US), and other licensees in Europe, Canada, Mexico, South America, Africa, Middle East, India, Southeast Asia, and South Korea.
3. CDMO Manufacturing Services: Contract development and manufacturing organization services offered through Pharmaloop subsidiary. FDA-approved sterile liquids manufacturing for third parties with 500 million sterile vials per year capacity.
4. Consumer Healthcare Products: OTC products including Cristalmina (chlorhexidine antiseptic), Herpix, and other consumer health supplements sold through pharmacies.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Core offering

Laboratorios Salvat develops, manufactures, and commercializes prescription and consumer healthcare pharmaceutical products focused primarily on otolaryngology (ear) and ophthalmology (eye), along with gastroenterology, urology, and self-care lines. The company operates proprietary Blow-Fill-Seal (BFS) aseptic manufacturing technology for sterile single-dose formulations and runs a CDMO business through its Pharmaloop subsidiary offering contract manufacturing for third parties.

Product overview

Laboratorios Salvat is a private pharmaceutical company established in Barcelona in 1955, specializing in the development and manufacture of prescription and consumer healthcare products. The company focuses primarily on otolaryngology (ear conditions) and ophthalmology (eye conditions), with additional presence in gastroenterology, urology, and consumer self-care. Key prescription products include Cetraxal Otico and Cetraxal Plus (otology treatments with unique ciprofloxacin combinations in single-dose vials), OTOVEL (pediatric ear infection treatment), Clotic (FDA-approved otomycosis treatment with Orphan Drug Designation), and Monolitum/Monolitum Flas (lansoprazole for ulcers and reflux). The consumer healthcare portfolio centers on the flagship Cristalmina antiseptic brand (chlorhexidine-based), the Relive eye care line (hyaluronic acid-based dry eye treatments), probiotic supplements (Megalevure), and various wellness products. Salvat operates with a CDMO (Contract Development and Manufacturing Organization) division offering Blow-Fill-Seal (BFS) sterile manufacturing technology, serving both its own product portfolio and third-party clients. The company maintains manufacturing facilities in Barcelona, Madrid (Pharmaloop), and Tamarac, Florida, with products marketed across otolaryngology, ophthalmology, gastroenterology, urology, and consumer healthcare therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• Salvat Foundation: Non-profit organization established in 1972, focused on innovation through a biannual prize for Research in Pharmaceutical Technology, and patronage of arts focusing on Music and Contemporary Art.

Products and services

• Cetraxal Otico Ciprofloxacin otic solution for the treatment of ear infections; first topical antibiotic otic product of its kind, available in single-dose preservative-free vials using BFS technology. Sold via pharmacies and healthcare providers.
• Cetraxal Plus Unique combination of ciprofloxacin and fluocinolone otic solution in single-dose preservative-free vials; first combination of its kind for ear infection treatment.
• OTOVEL Combination of ciprofloxacin (fluoroquinolone antibacterial) and fluocinolone acetonide (corticosteroid) indicated for acute otitis media with tympanostomy tubes in pediatric patients aged 6 months and older. Available in single-dose 0.25 mL vials.
• Clotic Clotrimazole-based treatment for otomycosis (fungal ear infections). FDA approved with Orphan Drug Designation, addressing an unmet clinical need in the management of fungal ear infections.
• Monolitum / Monolitum Flas Lansoprazole orally dispersible tablet (ODT) for acute treatment of duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease; leading OTC product for ulcer treatment, leveraging proprietary buccodispersible tablet technology.
• Cristalmina Chlorhexidine gluconate topical antiseptic available in multiple presentations (10 mg/ml drops, spray, gel, plus 20 mg/ml, and Hospital 2% aqueous solution). Spain's market-leading antiseptic and Salvat's flagship consumer brand.
• Ebernet Eberconazole topical antifungal; first new chemical entity (NCE) developed by Salvat to reach market, sold across three continents.
• Herpix Oral food supplement for Herpes Simplex Virus management, containing lysine, Echinacea purpurea, vitamin C, and zinc.
• Relive Eye Care Line Eye drop line including Relive Ojos Secos (hyaluronic acid and glycerin for dry eye), Relive Noche (with carboxymethylcellulose for nighttime use), Relive Sicca (with sodium hyaluronate, triglycerides, and castor oil), and Relive Total Care (with polyvinylpyrrolidone and cyanocobalamin).
• Ilmago Combination of dutasteride and tamsulosin hydrochloride for the treatment of benign prostatic hyperplasia (BPH).
• Tebarat / Tebarat 1 mg/ml Azelastine ophthalmic solution for eye allergies and azelastine hydrochloride nasal spray for allergic rhinitis.
• Tanolux Latanoprost ophthalmic solution for glaucoma treatment.
• Bimeox Bimatoprost ophthalmic product.
• Cetraflux Ciprofloxacin ophthalmic product.
• Ursitan Tobramycin ophthalmic product.
• Salvacolina / Salvacolina Flas Loperamide product (capsules and orally dispersible tablet) for symptomatic treatment of acute nonspecific diarrhea; first major brand launched by Salvat in 1959.
• Urosens Line Cranberry-based consumer supplement range for urinary tract health, including Urosens, Urosens forte (with ursolic acid), Urosens intense (with D-mannose and probiotic strains), and Urosens manosa.
• Levogastrol Levosulpiride product for gastrointestinal disorders.
• Megalevure Probiotic Line Probiotic supplements including Megalevure (with Saccharomyces boulardii, Lactobacillus rhamnosus GG, Lactobacillus helveticus, Bifidobacterium longum, FOS, and vitamin D3) and Megalevure Protransitus (with Lactobacillus Plantarum).
• Audiovit / Tinnitan Duo Ear health and tinnitus support supplements, including Audiovit (magnesium, Ginkgo biloba, melatonin) and Tinnitan Duo (L-tryptophan, Ginkgo biloba, magnesium, melatonin, vitamins B5/B6, zinc).
• Nasolina Oxymetazoline nasal decongestant.
• Pharmaloop CDMO Services Contract Development and Manufacturing Organization (CDMO) services for sterile liquid pharmaceuticals, leveraging BFS technology at an FDA-approved facility with capacity of 500 million sterile vials per year. Offered to third-party pharmaceutical companies.
• IMPACT-SVT Nanoemulsion (Clobetasol) Pioneering ocular corticosteroid (clobetasol) formulated in proprietary nanoemulsion for the treatment of inflammation and pain after ocular surgery, leveraging IMPACT-SVT nanoemulsion technology.

Quantifiable outcome

• Record €100+ million revenue with 25% EBITDA growth in 2025
• +4 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core, strategic and minor.

• WraSer PharmaceuticalscoreChannel Partner/ Reseller/ DistributorWraSer Pharmaceuticals commercializes Otovel (ciprofloxacin + fluocinolone) otic solution in the US market. Partnership began with launch of first FDA-approved product from Salvat in US market in 2016.
• Arbor Pharmaceuticals, LLCcoreChannel Partner/ Reseller/ DistributorJoint launch announcement with Salvat for OTOVEL in August 2016. Arbor commercializes the product in US market as the first and only antibiotic and steroid combination ear drop available in sterile, preservative-free single-dose vials.
• Lee's PharmaceuticalstrategicChannel Partner/ Reseller/ DistributorAgreement for distribution of Cetraxal Plus in China, Hong Kong, and Taiwan. Phase III clinical trial began January 2021 with 600 patients from 44 hospitals led by Fudan University researchers. Strategic market entry for Salvat in Chinese pharmaceutical market.
• HistocellstrategicStrategic or Co-development PartnerCollaboration on BONECURE project - innovative cell therapy for treatment of non-consolidated bone fractures using pre-differentiated mesenchymal stem cells. Phase II clinical trial completed with promising results.
• Histocell (BONECURE)strategicStrategic or Co-development PartnerBiopharmaceutical company specializing in regenerative medicine and cell therapies. Collaboration on Phase II clinical trial for bone fracture treatment conducted at Teknon Medical Center Barcelona and Hospital Universitario La Paz Madrid.
• PharmaloopcoreOEM/ Whitelabel/ Licensing PartnerWholly-owned subsidiary acquired in 2017 in Madrid. First fully autonomous pharmaceutical production center in Spain with BFS technology. FDA-approved for US market manufacturing. Offers contract development and manufacturing services to third parties.
• ICE JacexminorGTM or Marketing PartnerJapanese companies visited Pharmaloop facilities through ICEX and IcexJapon trade programs for potential business partnerships.
• INDREYE ConsortiumminorStrategic or Co-development PartnerConsortium for development of INDREYE research project 'Innovative solutions for the treatment and diagnosis of dry eye syndrome' funded by Spanish National Program INNPACTO, co-financed by European Union ERDF/FEDER.

Scale indicators10 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• Esteve: Privately-held Spanish pharmaceutical group with diversified specialty pharma, API manufacturing, and CDMO activities, comparable in ownership profile and breadth of pharma-plus-manufacturing model.
• Almirall: Largest Spanish-listed specialty pharma, with dermatology, ENT, and gastroenterology franchises and broader European/US commercial reach — a relevant scale benchmark for Salvat's specialty pharma ambitions.
• Bausch + Lomb: Global ophthalmology specialty business (part of Bausch Health) covering prescription ophthalmics, surgical, and consumer eye care — directly comparable to Salvat's ophthalmology franchise including the Relive dry-eye line and forthcoming clobetasol nanoemulsion.
• Catalent: Large global CDMO with broad sterile manufacturing and Blow-Fill-Seal capacity across multiple geographies; relevant as both a competitor to Pharmaloop and a valuation benchmark for BFS-based CDMO businesses.

Direct peers

• Faes Farma: Spanish specialty pharmaceutical company with overlapping ENT, OTC, and consumer healthcare franchises in Iberia and Latin America, similar mid-sized revenue profile and family-influenced shareholder base.
• Laboratorios Rovi: Spanish pharma with proprietary drug delivery technologies (e.g., ISM platform) and a CDMO/manufacturing services arm, directly comparable to Salvat's combination of branded specialty pharma plus a BFS-based CDMO.
• Reig Jofre: Barcelona-based mid-cap pharmaceutical company with specialties in ENT, dermatology, and sterile injectables CDMO services, overlapping Salvat in therapeutic focus, geography, and manufacturing services model.
• Recipharm: Global CDMO offering sterile liquid, Blow-Fill-Seal and aseptic manufacturing services to pharma customers — directly comparable to Pharmaloop's service offering and target customer base.
• Alliance Pharma: UK-listed specialty pharma focused on niche prescription and consumer healthcare brands distributed internationally — comparable in model of acquiring and commercializing niche specialty brands across multiple geographies.

Regional players

• Laboratorios Kern Pharma: Spanish generics and specialty pharma with hospital and CDMO services, overlapping Salvat in therapeutic breadth and Iberian footprint while competing in adjacent prescription and consumer segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/salvatpharma
• Facebookfacebook.com/salvatpharma
• LinkedInlinkedin.com/company/salvat

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorios Salvat